Wellington Management Group LLP Acquires 478,239 Shares of Immunome, Inc. $IMNM

Wellington Management Group LLP boosted its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 10.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,210,216 shares of the company’s stock after buying an additional 478,239 shares during the period. Wellington Management Group LLP’s holdings in Immunome were worth $110,404,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Renaissance Technologies LLC purchased a new position in shares of Immunome in the 1st quarter valued at $1,507,000. California State Teachers Retirement System lifted its stake in shares of Immunome by 66.3% during the 1st quarter. California State Teachers Retirement System now owns 111,444 shares of the company’s stock worth $2,437,000 after purchasing an additional 44,432 shares during the last quarter. Nan Fung Trinity HK Ltd. lifted its stake in shares of Immunome by 20.7% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 714,553 shares of the company’s stock worth $15,349,000 after purchasing an additional 122,450 shares during the last quarter. Bank of America Corp DE boosted its position in Immunome by 285.6% during the first quarter. Bank of America Corp DE now owns 781,607 shares of the company’s stock valued at $17,094,000 after purchasing an additional 578,890 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Immunome by 23.4% during the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after purchasing an additional 1,144,788 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Friday, July 17th. Truist Financial raised their price target on shares of Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Leerink Partners cut their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research report on Friday, May 15th. HC Wainwright reiterated a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Finally, Barclays started coverage on shares of Immunome in a research report on Thursday, May 28th. They set an “overweight” rating and a $36.00 target price for the company. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Immunome presently has an average rating of “Moderate Buy” and an average price target of $34.64.

Immunome Price Performance

Shares of NASDAQ:IMNM opened at $27.07 on Wednesday. The business’s 50-day moving average is $24.52 and its 200 day moving average is $22.48. Immunome, Inc. has a 1 year low of $8.66 and a 1 year high of $30.06. The firm has a market capitalization of $3.07 billion, a P/E ratio of -10.70 and a beta of 2.13.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). On average, analysts expect that Immunome, Inc. will post -2.38 EPS for the current year.

Insider Activity at Immunome

In related news, Director Isaac Barchas sold 101,050 shares of the stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $21.12, for a total value of $2,134,176.00. Following the completion of the transaction, the director directly owned 308,504 shares of the company’s stock, valued at $6,515,604.48. This trade represents a 24.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 90,616 shares of Immunome stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the completion of the sale, the insider owned 50,366 shares of the company’s stock, valued at $1,263,682.94. This trade represents a 64.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 682,310 shares of company stock worth $15,675,566. 7.21% of the stock is owned by insiders.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.